Board of Directors
Mr. Evans, of Rosetta Partners, a biotechnology investment firm, has raised the majority of equity funding for Atterx over the last eight years. He has been active as an investor in hedge funds and young start-up companies, and prior to that, traded options and commodities on the Chicago Board of Trade and Chicago Board Options Exchange for 20 years. He was an early partner in the Chicago Research and Trading Group.
Mr. Millar has over 20 years of financial and business expertise plus extensive management and business development experience as a senior executive with both large and earlier stage companies. As founder of The Vine Group, a business advisory group providing strategic planning, valuation analysis and financing assistance to growing businesses, Mr. Millar has advised, managed or led over 100 transactions with an aggregate value of over $1 billion.
Contact Jim Millar
James V. Millar
Chief Executive Officer
Dr. Watt has been with Atterx since 2006. Previous to joining Atterx, he held senior management positions as Director of Cell Biology & Transgenesis at Infigen, Inc. and as Director of Government Programs at OpGen, Inc. He received a B.Sc. and Ph.D. in Biochemistry and Microbiology from the University of Guelph, Canada followed by a post-doctoral position at the University of Texas, M.D. Anderson Cancer Center in Houston, TX. Dr. Watt has nearly 20 years of experience in the development of novel biologics/pharmaceuticals for various diseases/infections.
Contact Steve Watt
Steven R. Watt, Ph.D.
Chief Operating Officer and Chief Scientist
Mr. McCallum founded JAM Capital Partners with Carl Cummings in 2010 and has provided strategic advice to high net worth families in the Investment Management Division of Goldman Sachs & Co. Mr. McCallum has also served as a Legislative Aide to the Speaker of the United States House of Representatives, the Honorable Newt Gingrich, in Washington, DC. from 1993 until 1996.